Literature DB >> 24590295

Thyroid fine-needle aspiration: the relevance of BRAF mutation testing.

Giuseppe Di Benedetto1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24590295     DOI： 10.1007/s12020-014-0222-1

Source DB:  PubMed          Journal:  Endocrine        ISSN： 1355-008X            Impact factor:   3.633


× No keyword cloud information.
  11 in total

1.  BRAF mutation assessment in papillary thyroid cancer: are we ready to use it in clinical practice?

Authors:  Efisio Puxeddu; Sebastiano Filetti
Journal:  Endocrine       Date:  2013-12-24       Impact factor: 3.633

2.  Outcome of thyroid nodules characterized as atypia of undetermined significance or follicular lesion of undetermined significance and correlation with Ultrasound features and BRAF(V600E) mutation analysis.

Authors:  Sun Hye Jeong; Hyun Sook Hong; Eun Hye Lee; Jang Gyu Cha; Ji Sang Park; Jung Ja Kwak
Journal:  AJR Am J Roentgenol       Date:  2013-12       Impact factor: 3.959

3.  The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis.

Authors:  Tae Hyuk Kim; Young Joo Park; Jung Ah Lim; Hwa Young Ahn; Eun Kyung Lee; You Jin Lee; Kyung Won Kim; Seo Kyung Hahn; Yeo Kyu Youn; Kwang Hyun Kim; Bo Youn Cho; Do Joon Park
Journal:  Cancer       Date:  2011-08-31       Impact factor: 6.860

4.  Additional BRAF mutation analysis may have additional diagnostic value in thyroid nodules with "suspicious for malignant" cytology alone even when the nodules do not show suspicious US features.

Authors:  Jae Young Seo; Eun-Kyung Kim; Jin Young Kwak
Journal:  Endocrine       Date:  2014-01-23       Impact factor: 3.633

5.  Is the BRAF(V600E) mutation useful as a predictor of preoperative risk in papillary thyroid cancer?

Authors:  Jung Kwang Nam; Chan Kwon Jung; Byung Joo Song; Dong Jun Lim; Byung Joo Chae; Nam Seop Lee; Woo Chan Park; Jeong Soo Kim; Sang Seol Jung; Ja Seong Bae
Journal:  Am J Surg       Date:  2011-07-30       Impact factor: 2.565

6.  Clinical management of thyroid nodules with indeterminate cytology: our institutional experience using SIAPEC cytological criteria and V600-BRAF test.

Authors:  G Di Benedetto; A Fabozzi; C Rinaldi
Journal:  Pathologica       Date:  2013-02

7.  BRAF mutation analysis and sonography as adjuncts to fine-needle aspiration cytology of papillary thyroid carcinoma: their relationships and roles.

Authors:  Won-Jin Moon; Nami Choi; Jin Woo Choi; Suk Kyeong Kim; Tae Sook Hwang
Journal:  AJR Am J Roentgenol       Date:  2012-03       Impact factor: 3.959

8.  The BRAF(V600E) mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study.

Authors:  Rossella Elisei; David Viola; Liborio Torregrossa; Riccardo Giannini; Cristina Romei; Clara Ugolini; Eleonora Molinaro; Laura Agate; Agnese Biagini; Cristiana Lupi; Laura Valerio; Gabriele Materazzi; Paolo Miccoli; Paolo Piaggi; Aldo Pinchera; Paolo Vitti; Fulvio Basolo
Journal:  J Clin Endocrinol Metab       Date:  2012-10-12       Impact factor: 5.958

9.  The BRAF V600E mutation in papillary thyroid cancer with positive or suspected pre-surgical cytological finding is not associated with advanced stages or worse prognosis.

Authors:  Daniele Barbaro; Roberto Mario Incensati; Gabriele Materazzi; Giuseppe Boni; Mariano Grosso; Erica Panicucci; Paola Lapi; Cristina Pasquini; Paolo Miccoli
Journal:  Endocrine       Date:  2013-08-08       Impact factor: 3.633

Review 10.  [BRAF gene mutation in the natural history of papillary thyroid carcinoma: diagnostic and prognostic implications].

Authors:  J Pedro Lopes; E Fonseca
Journal:  Acta Med Port       Date:  2011-12-31
View more
  4 in total

1.  A combination of immunohistochemistry and molecular approaches improves highly sensitive detection of BRAF mutations in papillary thyroid cancer.

Authors:  Claudia Martinuzzi; Lorenza Pastorino; Virginia Andreotti; Anna Garuti; Michele Minuto; Roberto Fiocca; Giovanna Bianchi-Scarrà; Paola Ghiorzo; Federica Grillo; Luca Mastracci
Journal:  Endocrine       Date:  2015-08-22       Impact factor: 3.633

2.  The combination of TP53INP1, TP53INP2 and AXIN2: potential biomarkers in papillary thyroid carcinoma.

Authors:  Mengzi He; Yinlong Zhao; Heqing Yi; Hui Sun; Xiaodong Liu; Shumei Ma
Journal:  Endocrine       Date:  2014-08-09       Impact factor: 3.633

3.  Clinical significance of preoperative detection of serum p53 antibodies and BRAF(V600E) mutation in patients with papillary thyroid carcinoma.

Authors:  Qing-Feng Fu; Peng-Tao Pan; Le Zhou; Xiao-Li Liu; Feng Guo; Li Wang; Hui Sun
Journal:  Int J Clin Exp Med       Date:  2015-11-15

4.  Utility of including BRAF mutation analysis with ultrasonographic and cytological diagnoses in ultrasonography-guided fine-needle aspiration of thyroid nodules.

Authors:  Da Som Kim; Dong Wook Kim; Young Jin Heo; Jin Wook Baek; Yoo Jin Lee; Hye Jung Choo; Young Mi Park; Ha Kyoung Park; Tae Kwun Ha; Do Hun Kim; Soo Jin Jung; Ji Sun Park; Ki Jung Ahn; Hye Jin Baek; Taewoo Kang
Journal:  PLoS One       Date:  2018-08-17       Impact factor: 3.240
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.